China’s drug regulator directed that Sun Pharma’s rivastigmine hydrogen tartrate capsules stop being imported, sold, and used in China. The regulator cited deficiencies identified in a remote inspection, including contamination-prevention controls and quality management oversight. The action functions as a market access suspension for the product until the cited issues are addressed. Sun Pharma did not provide an immediate public response in the excerpt. The regulator’s stated basis centers on manufacturing process and quality-system compliance.